First-ever breast cancer patient journey study in sub-Saharan Africa
*Roche study aims to describe potential delays, factors influencing patient care
Roche has presented the study design for the first-ever breast cancer patient journey study in sub-Saharan Africa (SSA) at the African Organisation for Research and Training in Cancer (AORTIC) congress in Kigali, Rwanda. The study aims to describe the typical breast cancer patient journey, as well as to assess resource use, cost, and other hurdles influencing patient care in public and private hospitals in Kenya, Nigeria and Ghana.
The data will provide insight into the challenges of addressing the full spectrum of breast cancer patient care in SSA, and help identify what solutions are needed at multiple points in the patient journey. Full study data will be available in 2018.
Despite advances in management, breast cancer remains the leading cause of cancer death among women worldwide. The burden of breast cancer disproportionately affects African countries with five-year survival rates as low as 12 per cent in parts of Africa, compared with almost 90 per cent in the United States, Australia and Canada. In addition, as many as 80 per cent of patients in SSA are diagnosed with late-to-end stage disease when very little can be achieved in terms of curative treatment.
Limited resources also adversely impact access to care, resulting in sub-optimal management, high morbidity and mortality. This often places breast cancer patients and their families at risk of ﬁnancial hardship. Lack of financial burden data is a major obstacle to developing policies for cancer care in lower middle-income countries.
No comments yet